TLS data
 

BioCommunique

Corporate Newsletter

 
 
Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Ambys Launches with $140M Plus Takeda Partnership, OncoSec Enters Research Collaboration Agreement with UCLA, Harpoon Therapeutics Treats First Prostate Cancer Patient with HPN424

  • Fri Aug 10 22:26:00 GMT 2018
  • California
  • Author Lauren Panetta


8/8/18 - Endpoints News
Third Rock’s Ambys hauls $140M for liver disease, inking Takeda deal ahead of launch

8/8/18 - Cellular Biomedicine Group
Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights

8/8/18 - Alector
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

8/8/18 - Heron Therapeutics
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

8/7/18 - Sunesis Pharmaceuticals 
Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights

8/7/18 - NovaBay Pharma
NovaBay Pharma Reports Second Quarter 2018 Financial Results

8/7/18 - FibroGen
FibroGen Reports Second Quarter 2018 Financial Results

8/7/18 - Scripps Research
Researchers look to worms for a new model of a peripheral nervous system disease

8/7/18 - Halozyme
Halozyme Reports Second Quarter 2018 Results

8/6/18 - Biocept
Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs

8/6/18 - OncoSec
OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.

8/6/18 - Otonomy
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication

8/6/18 - Harpoon Therapeutics
Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

8/6/18 - Pliant Therapeutics
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

8/3/18 - Pulse Biosciences
Pulse Biosciences Grants Equity Incentive Awards to New Employees

8/3/18 - San Francisco Business Times
Alexandria’s Joel Marcus on Medicare-for-all, innovation and his company’s Peninsula plans

8/3/18 - Wired
23andMe’s Pharma Deals Have Been the Plan All Along
 

 
 

Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.

 
 

Related Articles View All

 
Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.
 
Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.
 
Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.